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Context
Vector-borne diseases represent more than 17 percent of all infectious sicknesses and affect
millions of people each year.1 Among them, malaria is the most important causing more
than 400 000 deaths and 216 million of cases. This parasitosis is caused by a protozoan
belonging to the Plasmodium genus. More than 90% of cases and deaths following malaria
are linked to P. falciparum which is transmitted thanks to mosquitoes from Anopheles
family.2
While many efforts are consent to develop a vaccine, chemotherapy remains the most valid
therapeutic strategy, nowadays. Combination of artemisinin derivatives (artemether,
artesunate) and a long acting agent such as lumefantrine, amodiaquine, mefloquine… are
particularly recommended. Unfortunately, as for antibiotics, resistance to antimalarials
emerge from their use. Considering this resistance and the prevalence of malaria,
development of new antiplasmodials represents an urgent need.3
Objectives
Nature remains an important source of medicinal compounds4. Screening of natural molecules
identified from plants used in traditional medicine leads to identification of metabolites which are
active against Plasmodium’s strains, including the one which are resistant to modern
antiplasmodials.
Among the candidates, ellagic acid (EA, 1) seems to be one of the most promising compound
thanks to its proven in vitro efficacy (105-330 nM) and in vivo activity after intraperitoneal
injection. Interestingly, no toxic effect could be demonstrated at >5 g/kg (per os) or 1g/kg/d (IP).
This polyphenolic compound seems thus very attractive for malaria treatment.5 However, EA
suffers from a poor oral bioavailability, partly explained by a reduced water solubility (9.7 µg/mL)
itself linked to strong intermolecular bounds6.
The aim of our work is the design and the preparation of crowded analogues and prodrugs with
enhanced solubility and by extension, improved bioavailability which would permit its oral use.
Pharmacomodulation
As described in Fig.1 , taking advantage of phenolic functions, we plan to 
insert bulky/polar chains on selected positions. This should lead to crowded
analogues of EA. The planned pharmacomodulations should also give insights 
about the pharmacophore of this polyphenol.
Antiplasmodial effect
In order to explore the effect of substituted dervivatives on malaria parasite, final compounds and all the 
intermediates are submitted in an in vitro assay to determine their inhibitory effect, expressed as IC50 (µM), on 
3D7 strain of Plasmodium falciparum (chloroquin-sensitive). This evaluation follows the procedure established by 
Frederich et al. (2002)8 and is based on colorimetric measure of Plasmodium lactate deshydrogenase activity9
realized at least in triplicates.
Product 
(n=)
R R1/R3 R2/R4 IC50 (µM)
1 / H H IP
2 (3)
H H H 125,19±5,76
3 (3)
CH3 H H 118,14±16,62
4 (2)
CH3 CH3CO CH3CO 47,29±17,98
5 (3)
CH3 BnCH2 CH3CO 33,27±12,86
6 (3)
CH3 BnCH2 H 54,11±13,02
7 (1)
CH3 BnCH2 MOM 43,83
8 (3)
H BnCH2 MOM 58,74±28,25
9 (4)
CH2CH3CH2OPMB BnCH2 MOM 19,89±4,16
10 (2)
CH2CH3CH2OH BnCH2 MOM 82,02±15,64
11 (2)
CH2CH3CH2 BnCH2 MOM 17,19±5,23
12 (2)
CH2CH3CH2 BnCH2 H 3,67±0,19
13
CH2CH3CH2 BnCH2 H IP
14
/ BnCH2 H IP
Conclusion & Prospects
As observed during the pharmacological assay, some intermediates showed a higher effect ( < 125 µM)  than gallic
acid (2). Interestingly, this inhibitory activity clearly increases when there is a linker between 2 gallate moieties.  
This observation suggests the importance to look like as a dimer to observe the same rank of potency of EA.
We can also observe that substituants on the phenolic functions seem to negatively impact this effect (11 vs 12). 
The next step will be testing against 3D7 to confirm pharmacological results and the final substituted compound. 
Moreover, other mono- and disubstituted derivatives of EA’s scaffold will be synthetized. Another part of the 
future work will consist to determine the aqueous solubility of the new compounds vs EA.
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Fig. 1 Pharmacomodulation opportunities
Synthesis
Considering issues encountered following a direct synthesis approach, a total synthesis strategy is preferred in 
order to obtain the desired molecules.7,8
i CH3OH, H2SO4 ii Ac2O, H2SO4 iii BnBr, KI, K2CO3, acetone iv K2CO3 , CH3OH, H2O v NaH, MOMCl, DMF vi LiOH, CH3OH, THF, H2O vii 
1,3-propanediol-PMB, DMAP, EDCI-HCl, CH2Cl2 viii DDQ, Sorenson’s buffer, CH2Cl2 ix DMAP, EDCI-HCl, CH2Cl2 x THF, IPA/HCl xi 
CuCL2 , n-BuNH2, CH3OH xii LiOH, CH3OH, THF, H2O 
IP = In Progress
